Yen‐Hwa Chang - Concepedia

Author

Yen‐Hwa Chang

Taipei Veterans General Hospital

Also Known As

Monserrat Domenech, YEN-HWA CHANG, Yen-Hwa Chang, Yen‐Hwa Chang

Publications

Citations

H-Index

Concepts

All Affiliations

Taipei Veterans General Hospital National Yang Ming Chiao Tung University Merck & Co., Inc., Rahway, NJ, USA (United States)Queen Mary University of London University College London

About

Yen‐Hwa Chang is an author at Taipei Veterans General Hospital specializing in medicine, urology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	903
2	Surgical Oncology	4	4	112
3	Immunology	3	3	102
4	Cell Biology	1	1	36
5	Nephrology	1	1	10

Yen‐Hwa Chang

Publications

6.4K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Brian I. Rini, Elizabeth R. Plimack, V.P. Stus, New England Journal of Medicine	2019	3.3K
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy Alain Ravaud, Robert J. Motzer, Hardev Pandha, New England Journal of Medicine	2016	757
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, New England Journal of Medicine	2021	708
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study Elizabeth R. Plimack, Thomas Powles, V.P. Stus, European Urology UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorFirst-line Treatment	2023	118
Are There Useful CT Features to Differentiate Renal Cell Carcinoma From Lipid-Poor Renal Angiomyolipoma? Ching‐Wei Yang, Shu-Huei Shen, Yen‐Hwa Chang, American Journal of Roentgenology	2013	117
Immunohistochemical and molecular genetic profiling of acquired cystic disease‐associated renal cell carcinoma Chin‐Chen Pan, Yann‐Jang Chen, Liang‐Che Chang, Histopathology	2009	78
Clinicopathological and molecular characterisation of papillary renal neoplasm with reverse polarity and its renal papillary adenoma analogue Hsin‐Yi Chang, Jen‐Fan Hang, Chih‐Ying Wu, Histopathology	2020	44
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Journal of Clinical Oncology Surgical OncologyRenal PathologyImmunologyImmunoeditingImmunotherapeutics	2021	38

Page 1